According to Zacks, “Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company’s lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France. “
GNFT has been the topic of a number of other reports. HC Wainwright upgraded Genfit from a neutral rating to a buy rating and set a $8.00 price objective on the stock in a research report on Monday, December 20th. Oddo Bhf raised Genfit to a buy rating in a research note on Friday, December 17th. Finally, SVB Leerink cut their price target on Genfit from $15.00 to $10.00 and set an outperform rating on the stock in a research note on Monday, April 11th.
Hedge funds have recently bought and sold shares of the company. Credit Suisse AG acquired a new position in shares of Genfit in the 4th quarter valued at $55,000. OLD Mission Capital LLC acquired a new position in shares of Genfit in the 3rd quarter valued at $213,000. Morgan Stanley raised its stake in Genfit by 76.7% during the 1st quarter. Morgan Stanley now owns 64,071 shares of the company’s stock worth $296,000 after buying an additional 27,818 shares during the period. Finally, Millennium Management LLC raised its stake in Genfit by 23.3% during the 4th quarter. Millennium Management LLC now owns 392,517 shares of the company’s stock worth $1,963,000 after buying an additional 74,068 shares during the period. 1.22% of the stock is currently owned by institutional investors.
Genfit Company Profile (Get Rating)
Genfit SA, a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis.
- Get a free copy of the StockNews.com research report on Genfit (GNFT)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.